124 related articles for article (PubMed ID: 15923344)
1. A novel, long-acting agonist of glucose-dependent insulinotropic polypeptide suitable for once-daily administration in type 2 diabetes.
Irwin N; Green BD; Mooney MH; Greer B; Harriott P; Bailey CJ; Gault VA; O'Harte FP; Flatt PR
J Pharmacol Exp Ther; 2005 Sep; 314(3):1187-94. PubMed ID: 15923344
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the antidiabetic activity of DPP IV resistant N-terminally modified versus mid-chain acylated analogues of glucose-dependent insulinotropic polypeptide.
Irwin N; Clarke GC; Green BD; Greer B; Harriott P; Gault VA; O'Harte FP; Flatt PR
Biochem Pharmacol; 2006 Sep; 72(6):719-28. PubMed ID: 16859646
[TBL] [Abstract][Full Text] [Related]
3. Fatty acid derivatised analogues of glucose-dependent insulinotropic polypeptide with improved antihyperglycaemic and insulinotropic properties.
Kerr BD; Irwin N; O'Harte FP; Bailey CJ; Flatt PR; Gault VA
Biochem Pharmacol; 2009 Oct; 78(8):1008-16. PubMed ID: 19523458
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the subchronic antidiabetic effects of DPP IV-resistant GIP and GLP-1 analogues in obese diabetic (ob/ob) mice.
Irwin N; McClean PL; Flatt PR
J Pept Sci; 2007 Jun; 13(6):400-5. PubMed ID: 17486662
[TBL] [Abstract][Full Text] [Related]
5. Effects on glucose homeostasis and insulin secretion of long term activation of the glucose-dependent insulinotropic polypeptide (GIP) receptor by N-AcGIP(LysPAL37) in normal mice.
Irwin N; Green BD; Gault VA; Cassidy RS; O'Harte FP; Harriott P; Flatt PR
Peptides; 2006 Apr; 27(4):893-900. PubMed ID: 16181707
[TBL] [Abstract][Full Text] [Related]
6. Antidiabetic potential of two novel fatty acid derivatised, N-terminally modified analogues of glucose-dependent insulinotropic polypeptide (GIP): N-AcGIP(LysPAL16) and N-AcGIP(LysPAL37).
Irwin N; Gault VA; Green BD; Greer B; Harriott P; Bailey CJ; Flatt PR; O'Harte FP
Biol Chem; 2005 Jul; 386(7):679-87. PubMed ID: 16207089
[TBL] [Abstract][Full Text] [Related]
7. Improved stability, insulin-releasing activity and antidiabetic potential of two novel N-terminal analogues of gastric inhibitory polypeptide: N-acetyl-GIP and pGlu-GIP.
O'Harte FP; Gault VA; Parker JC; Harriott P; Mooney MH; Bailey CJ; Flatt PR
Diabetologia; 2002 Sep; 45(9):1281-91. PubMed ID: 12242461
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the anti-diabetic effects of GIP- and GLP-1-receptor activation in obese diabetic (ob/ob) mice: studies with DPP IV resistant N-AcGIP and exendin(1-39)amide.
Irwin N; McClean PL; Cassidy RS; O'harte FP; Green BD; Gault VA; Harriott P; Flatt PR
Diabetes Metab Res Rev; 2007 Oct; 23(7):572-9. PubMed ID: 17315241
[TBL] [Abstract][Full Text] [Related]
9. Degradation, insulin secretion, and antihyperglycemic actions of two palmitate-derivitized N-terminal pyroglutamyl analogues of glucose-dependent insulinotropic polypeptide.
Irwin N; Green BD; Gault VA; Greer B; Harriott P; Bailey CJ; Flatt PR; O'Harte FP
J Med Chem; 2005 Feb; 48(4):1244-50. PubMed ID: 15715491
[TBL] [Abstract][Full Text] [Related]
10. Administration of an acylated GLP-1 and GIP preparation provides added beneficial glucose-lowering and insulinotropic actions over single incretins in mice with Type 2 diabetes and obesity.
Gault VA; Kerr BD; Harriott P; Flatt PR
Clin Sci (Lond); 2011 Aug; 121(3):107-17. PubMed ID: 21332446
[TBL] [Abstract][Full Text] [Related]
11. Chemical ablation of gastric inhibitory polypeptide receptor action by daily (Pro3)GIP administration improves glucose tolerance and ameliorates insulin resistance and abnormalities of islet structure in obesity-related diabetes.
Gault VA; Irwin N; Green BD; McCluskey JT; Greer B; Bailey CJ; Harriott P; O'harte FP; Flatt PR
Diabetes; 2005 Aug; 54(8):2436-46. PubMed ID: 16046312
[TBL] [Abstract][Full Text] [Related]
12. Antagonistic effects of two novel GIP analogs, (Hyp3)GIP and (Hyp3)GIPLys16PAL, on the biological actions of GIP and longer-term effects in diabetic ob/ob mice.
O'Harte FP; Hunter K; Gault VA; Irwin N; Green BD; Greer B; Harriott P; Bailey CJ; Flatt PR
Am J Physiol Endocrinol Metab; 2007 Jun; 292(6):E1674-82. PubMed ID: 17299087
[TBL] [Abstract][Full Text] [Related]
13. Improved glycaemic control in obese diabetic ob/ob mice using N-terminally modified gastric inhibitory polypeptide.
O'Harte FP; Mooney MH; Kelly CM; Flatt PR
J Endocrinol; 2000 Jun; 165(3):639-48. PubMed ID: 10828847
[TBL] [Abstract][Full Text] [Related]
14. Early administration of the glucose-dependent insulinotropic polypeptide receptor antagonist (Pro3)GIP prevents the development of diabetes and related metabolic abnormalities associated with genetically inherited obesity in ob/ob mice.
Irwin N; McClean PL; O'Harte FP; Gault VA; Harriott P; Flatt PR
Diabetologia; 2007 Jul; 50(7):1532-40. PubMed ID: 17486314
[TBL] [Abstract][Full Text] [Related]
15. Effects of subchronic treatment with the long-acting glucose-dependent insulinotropic polypeptide receptor agonist, N-AcGIP, on glucose homeostasis in streptozotocin-induced diabetes.
Gault VA; McClean PL; Irwin N; Power GJ; McCluskey JT; Flatt PR
Pancreas; 2007 Jul; 35(1):73-9. PubMed ID: 17575548
[TBL] [Abstract][Full Text] [Related]
16. GIP(Lys16PAL) and GIP(Lys37PAL): novel long-acting acylated analogues of glucose-dependent insulinotropic polypeptide with improved antidiabetic potential.
Irwin N; O'Harte FP; Gault VA; Green BD; Greer B; Harriott P; Bailey CJ; Flatt PR
J Med Chem; 2006 Feb; 49(3):1047-54. PubMed ID: 16451070
[TBL] [Abstract][Full Text] [Related]
17. A novel acylated form of (d-Ala(2))GIP with improved antidiabetic potential, lacking effect on body fat stores.
Martin CM; Irwin N; Flatt PR; Gault VA
Biochim Biophys Acta; 2013 Jun; 1830(6):3407-13. PubMed ID: 23518200
[TBL] [Abstract][Full Text] [Related]
18. Glucagon receptor antagonist and GIP agonist combination for diet-induced obese mice.
McShane LM; Irwin N; O'Flynn D; Franklin ZJ; Hewage CM; O'Harte FP
J Endocrinol; 2016 Jun; 229(3):319-30. PubMed ID: 27098830
[TBL] [Abstract][Full Text] [Related]
19. (Pro(3))GIP[mPEG]: novel, long-acting, mPEGylated antagonist of gastric inhibitory polypeptide for obesity-diabetes (diabesity) therapy.
McClean PL; Irwin N; Hunter K; Gault VA; Flatt PR
Br J Pharmacol; 2008 Nov; 155(5):690-701. PubMed ID: 18695644
[TBL] [Abstract][Full Text] [Related]
20. A comparison of the cellular and biological properties of DPP-IV-resistant N-glucitol analogues of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide.
Green BD; Gault VA; O'Harte FP; Flatt PR
Diabetes Obes Metab; 2005 Sep; 7(5):595-604. PubMed ID: 16050953
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]